About Intabio
Intabio is a Healthcare company based in Sunnyvale (United States) founded in 2015 by Lena Wu and Erik Gentalen, and was acquired by SCIEX in January 2021. Analytical platform for biotherapeutic drug quality characterization is offered. Intabio has raised $30.7 million across 4 funding rounds from investors including SCIEX, Genoa Ventures and Vertical Venture Partners. Its chief executive, as recorded, is Lena Wu. The company was acqui-hired. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Proteomics. Its competitors include Biological Dynamics, Epicore Biosystems and Miroculus; 3 of its 3 listed competitors have raised funding.
Company details
Intabio provides an analytical platform to accelerate the development of biotherapeutic drugs. It is developing an instrumentation system called Blaze comprised of a bench-top instrument, microfluidic chip, and reagent kit. The system uses a proprietary microfluidic platform and provides separation of intact protein isoforms by charge heterogeneity analysis (cIEF), imaging at 280nm for quantitation of each protein isoform, and sample preparation and electrospray delivery into an adjacent mass spectrometer in order to identify the unknown modifications. Claims that by enabling the interrogation of product quality earlier in the development process, the system provides insights for key development decisions and can reduce the risk of downstream bioproduction issues.
- Headquarters Sunnyvale, United States
- Founders Lena Wu, Erik Gentalen
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website intabio.com
- Social LinkedIn X
- Acquired by SCIEX (Jan 2021)
Funding Insights of Intabio
Intabio has successfully raised a total of $30.7M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $18 million completed in February 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $30.7M
- Total Rounds 4
- Last Round Series B — $18M
- First Round $3.2M
(Sep 2017)
- Investors Count 6
All 4 funding rounds of Intabio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2020 | $18M | Series B | – | Northpond Ventures | |
| Oct 2018 | $9.5M | Series A | – | Northpond Ventures | |
| Jan 2018 | $224,996 | Grant | – | – | |
| Sep 2017 | $3.2M | Seed | – | Jenny Rooke |
7 investors in total: 6 institutional and 1 angel.
Investors in Intabio
Intabio has secured backing from 7 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include SCIEX, Genoa Ventures and Vertical Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage VC firm focused on life science startups | genoavc.com | San Francisco, United States | ||
Early-stage venture capital investments are made in specific industry verticals. | vvp.vc | Palo Alto, United States | ||
Venture capital firm investing in life sciences & tech sectors | npv.vc | Cambridge, United States | ||
Offline & Life-Sciences sectors focused VC firm investing in geographies such as the US | morgannoble.com | Washington, Dc, United States | ||
A government-backed foundation providing seed-stage investments to support small businesses. | 1950 | nsf.gov | Arlington, United States | |
JR Jenny Rooke | Founder of Genoa Ventures, biotech investor, ex-Bill & Melinda Gates Foundation | unknown_c23dbcc6b38a41dca | ||
Scientific instrumentation, software, and services for life sciences are provided. | 1970 | sciex.com | Boston, United States |
Investor details for Intabio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Intabio
267 people are tracked at Intabio (74 in leadership, 193 in team).
| Name | Role | Group |
|---|---|---|
Lena Wu | Co-Founder, CEO & President | Leadership |
Erik Gentalen | Founder | Leadership |
Erik Schranz | Senior Director Customer Service | Leadership |
John McNamara | Director, Global Customer Experience And Education | Leadership |
Thomas Gordon | Director Of Manufacturing | Leadership |
Peter Goebel | Director, Open Innovation & Business Development | Leadership |
Joe Fox | President | Leadership |
Chris Apicerno | CFO & Global VP, Finance & IT | Leadership |
Chris Lock | VP, Global R&D | Leadership |
Carli Stoller | VP, Human Resources & Internal Communications | Leadership |
Phil Kilby | Senior Director - Innovation, Business Development & Strategy | Leadership |
Blaine Rehkopf | Global Director, IT Governance & Risk | Leadership |
Chikako Konomi | Commercial Director | Leadership |
Mike Cowhig | VP & General Counsel, SCIEX & Life Sciences Instruments Group | Leadership |
Mi Lee | Sr. Director, Fp&a | Leadership |
Usman Habib | VP, Strategy & Business Development | Leadership |
Micael Morvik | VP, Global Operations | Leadership |
Stefano Caso | Director Business Controlling & Sales Operation | Leadership |
David Ortiz | Senior Director Aftermarket Mgt. | Leadership |
Brenda Newton | VP, Quality Assurance & Regulatory Affairs | Leadership |
247 more people are available in the full profile.
Complete people profiles for Intabio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Intabio
4 dated milestones of Intabio across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Intabio is founded.
- Funding First funding round of $3.2M.
- Funding Latest funding round, Series B, of $18.0M.
- Exit Acquired by SCIEX.
Competitors of Intabio
Intabio has 3 listed competitors in our database, 3 of them funded. They include Biological Dynamics, Epicore Biosystems and Miroculus.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biologicaldynamics.com | 2010 | San Diego, United States | $67.65M | 54 | Proprietary lab-on-chip platform for nanoparticle isolation is offered. | |
| epicorebiosystems.com | 2017 | Cambridge, United States | $43.89M | Wearable sweat-based microfluidic sensing systems are provided for health monitoring. | ||
| miroculus.com | 2014 | San Francisco, United States | $48.42M | MicroRNA profiling platform is developed to detect genes in samples. |
Detailed competitors of Intabio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Intabio (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Intabio
Complete news archive for Intabio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Intabio
Intabio was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Intabio is headquartered in Sunnyvale, United States. It is registered at Sunnyvale, California, United States.
Lena Wu is the CEO of Intabio, as recorded in our data. They have also founded this company.
Intabio is a funded company, having raised a total of $30.7M across 4 funding rounds to date. The company's 1st funding round was a Seed of $3.2M, raised on Sep 2017.
Intabio provides an analytical platform to accelerate the development of biotherapeutic drugs. It is developing an instrumentation system called Blaze comprised of a bench-top instrument, microfluidic chip, and reagent kit. The system uses a proprietary microfluidic platform and provides separation of intact protein isoforms by charge heterogeneity analysis (cIEF), imaging at 280nm for quantitation of each protein isoform, and sample preparation and electrospray delivery into an adjacent mass spectrometer in order to identify the unknown modifications. Claims that by enabling the interrogation of product quality earlier in the development process, the system provides insights for key development decisions and can reduce the risk of downstream bioproduction issues.
Intabio's top competitors include Epicore Biosystems, Biological Dynamics and Miroculus.
Intabio has 7 investors. Key investors include SCIEX, Genoa Ventures, Vertical Venture Partners, Northpond Ventures, and National Science Foundation.
Yes. Intabio was acquired by SCIEX in January 2021.